Neovascular Glaucoma Questions & Answers

1. Havens SJ, Gulati V. Neovascular Glaucoma. Dev Ophthalmol. 2016. 55:196-204. [QxMD MEDLINE Link].

2. Simha A, Braganza A, Abraham L, Samuel P, Lindsley K. Anti-vascular endothelial growth factor for neovascular glaucoma. Cochrane Database Syst Rev. 2013 Oct 2. 10:CD007920. [QxMD MEDLINE Link].

3. Matsui N, Kamao T, Azumi A. [Case of metastatic intraocular malignant lymphoma with neovascular glaucoma]. Nippon Ganka Gakkai Zasshi. 2005 Jul. 109(7):434-9. [QxMD MEDLINE Link].

4. Bellotti A, Labbe A, Fayol N, El Mahtoufi A, Baudouin C. [OCT and neovascular glaucoma]. J Fr Ophtalmol. 2007 Jun. 30(6):586-91. [QxMD MEDLINE Link].

5. The Central Vein Occlusion Study Group. A randomized clinical trial of early panretinal photocoagulation for ischemic central vein occlusion. The Central Vein Occlusion Study Group N report. Ophthalmology. 1995 Oct. 102(10):1434-44. [QxMD MEDLINE Link].

6. Hasanreisoglu M, Weinberger D, Mimouni K, Luski M, Bourla D, Kramer M, et al. Intravitreal bevacizumab as an adjunct treatment for neovascular glaucoma. Eur J Ophthalmol. 2009 Jul-Aug. 19(4):607-12. [QxMD MEDLINE Link].

7. Lüke J, Nassar K, Lüke M, Grisanti S. Ranibizumab as adjuvant in the treatment of rubeosis iridis and neovascular glaucoma-results from a prospective interventional case series. Graefes Arch Clin Exp Ophthalmol. 2013 Oct. 251(10):2403-13. [QxMD MEDLINE Link].

8. Higashide T, Ohkubo S, Sugiyama K. Long-Term Outcomes and Prognostic Factors of Trabeculectomy following Intraocular Bevacizumab Injection for Neovascular Glaucoma. PLoS One. 2015. 10 (8):e0135766. [QxMD MEDLINE Link].

9. Li XJ, Yang XP, Li QM, Wang YY, Lyu XB. Ranibizumab Plus Combined Surgery for Treatment of Neovascular Glaucoma with Vitreous Hemorrhage. Chin Med J (Engl). 2015 Aug 5. 128 (15):2078-83. [QxMD MEDLINE Link].

10. Andreoli CM, Miller JW. Anti-vascular endothelial growth factor therapy for ocular neovascular disease. Curr Opin Ophthalmol. 2007 Nov. 18(6):502-8. [QxMD MEDLINE Link].

11. Simha A, Braganza A, Abraham L, Samuel P, Lindsley K. Anti-vascular endothelial growth factor for neovascular glaucoma. Cochrane Database Syst Rev. 2009. 3:

12. Ishibashi S, Tawara A, Sohma R, Kubota T, Toh N. Angiographic changes in iris and iridocorneal angle neovascularization after intravitreal bevacizumab injection. Arch Ophthalmol. 2010 Dec. 128(12):1539-45. [QxMD MEDLINE Link].

13. Higashide T, Murotani E, Saito Y, Ohkubo S, Sugiyama K. Adverse events associated with intraocular injections of bevacizumab in eyes with neovascular glaucoma. Graefes Arch Clin Exp Ophthalmol. 2012 Apr. 250(4):603-10. [QxMD MEDLINE Link].

14. Ehlers JP, Spirn MJ, Lam A, Sivalingam A, Samuel MA, Tasman W. Combination intravitreal bevacizumab/panretinal photocoagulation versus panretinal photocoagulation alone in the treatment of neovascular glaucoma. Retina. 2008 May. 28(5):696-702. [QxMD MEDLINE Link].

15. Martinez-Carpio PA, Bonafonte-Marquez E, Heredia-Garcia CD, Bonafonte-Royo S. [Efficacy and safety of intravitreal injection of bevacizumab in the treatment of neovascular glaucoma: systematic review]. Arch Soc Esp Oftalmol. 2008 Oct. 83(10):579-88. [QxMD MEDLINE Link].

16. Wakabayashi T, Oshima Y, Sakaguchi H, Ikuno Y, Miki A, Gomi F, et al. Intravitreal bevacizumab to treat iris neovascularization and neovascular glaucoma secondary to ischemic retinal diseases in 41 consecutive cases. Ophthalmology. 2008 Sep. 115(9):1571-80, 1580.e1-3. [QxMD MEDLINE Link].

17. Lee SJ, Lee JJ, Kim SY, Kim SD. Intravitreal bevacizumab (Avastin) treatment of neovascular glaucoma in ocular ischemic syndrome. Korean J Ophthalmol. 2009 Jun. 23(2):132-4. [QxMD MEDLINE Link]. [Full Text].

18. Kotecha A, Spratt A, Ogunbowale L, et al. Intravitreal bevacizumab in refractory neovascular glaucoma: a prospective, observational case series. Arch Ophthalmol. 2011 Feb. 129(2):145-50. [QxMD MEDLINE Link].

19. Takihara Y, Inatani M, Fukushima M, Iwao K, Iwao M, Tanihara H. Trabeculectomy with mitomycin C for neovascular glaucoma: prognostic factors for surgical failure. Am J Ophthalmol. 2009 May. 147(5):912-8, 918.e1. [QxMD MEDLINE Link].

20. Cheng Y, Liu XH, Shen X, Zhong YS. Ahmed valve implantation for neovascular glaucoma after 23-gauge vitrectomy in eyes with proliferative diabetic retinopathy. Int J Ophthalmol. 2013. 6(3):316-20. [QxMD MEDLINE Link]. [Full Text].

21. Luke J, Luke M, Grisanti S. [Antiangiogenic treatment for neovascular glaucoma and after filtering surgery]. Ophthalmologe. 2009 May. 106(5):407-12. [QxMD MEDLINE Link].

22. Gupta V, Jha R, Rao A, Kong G, Sihota R. The effect of different doses of intracameral bevacizumab on surgical outcomes of trabeculectomy for neovascular glaucoma. Eur J Ophthalmol. 2009 May-Jun. 19(3):435-41. [QxMD MEDLINE Link].

23. Falavarjani KG, Modarres M, Nazari H. Therapeutic effect of bevacizumab injected into the silicone oil in eyes with neovascular glaucoma after vitrectomy for advanced diabetic retinopathy. Eye (Lond). 2009 May 1. [QxMD MEDLINE Link].

24. Eid TM, Radwan A, el-Manawy W, el-Hawary I. Intravitreal bevacizumab and aqueous shunting surgery for neovascular glaucoma: safety and efficacy. Can J Ophthalmol. 2009 Aug. 44(4):451-6. [QxMD MEDLINE Link].

25. Albert DM, Jakobiec FA. Neovascular glaucoma. Principles and Practice of Ophthalmology, Clinical Ophthalmology [book on CD-ROM]. Chapter 215.

26. Browning DJ, Scott AQ, Peterson CB. The risk of missing angle neovascularization by omitting screening gonioscopy in acute central retinal vein occlusion. Ophthalmology. 1998 May. 105(5):776-84. [QxMD MEDLINE Link].

27. Epstein DL, Allingham RR, Schuman JS. Chandler and Grant's Glaucoma. 4th ed. 1997. 309-18.

28. Gupta V, Agarwal HC. Contact trans-scleral diode laser cyclophotocoagulation treatment for refractory glaucomas in the Indian population. Indian J Ophthalmol. 2000 Dec. 48(4):295-300. [QxMD MEDLINE Link].

29. Lieberman MF, Ewing RH. Drainage implant surgery for refractory glaucoma. Int Ophthalmol Clin. 1990 Summer. 30(3):198-208. [QxMD MEDLINE Link].

30. Moraczewski AL, Lee RK, Palmberg PF, Rosenfeld PJ, Feuer WJ. Outcomes of treatment of neovascular glaucoma with intravitreal bevacizumab. Br J Ophthalmol. 2009 May. 93(5):589-93. [QxMD MEDLINE Link].

31. Muller VA, Ruokonen P, Schellenbeck M, et al. Treatment of rubeosis iridis with photodynamic therapy with verteporfin--A new therapeutic and prophylactic option for patients with the risk of neovascular glaucoma?. Ophthalmic Res. 2003 Jan-Feb. 35(1):60-4. [QxMD MEDLINE Link].

32. Parodi MB, Iacono P. Photodynamic therapy with verteporfin for anterior segment neovascularizations in neovascular glaucoma. Am J Ophthalmol. 2004 Jul. 138(1):157-8. [QxMD MEDLINE Link].

33. Schlote T, Derse M, Rassmann K. Efficacy and safety of contact transscleral diode laser cyclophotocoagulation for advanced glaucoma. J Glaucoma. 2001 Aug. 10(4):294-301. [QxMD MEDLINE Link].

34. Shields MB. Textbook of Glaucoma. 4th ed. 1998. 269-86.

35. Sivak-Callcott JA, O'Day DM, Gass JD, Tsai JC. Evidence-based recommendations for the diagnosis and treatment of neovascular glaucoma. Ophthalmology. 2001 Oct. 108(10):1767-76; quiz1777, 1800. [QxMD MEDLINE Link].

36. Tripathi RC, Li J, Tripathi BJ. Increased level of vascular endothelial growth factor in aqueous humor of patients with neovascular glaucoma. Ophthalmology. 1998 Feb. 105(2):232-7. [QxMD MEDLINE Link].

Hemang K Pandya, MD, FACS Vitreoretinal Specialist, Dallas Retina Center; President, American Retina Forum

Hemang K Pandya, MD, FACS is a member of the following medical societies: American Academy of Ophthalmology, American Society of Retina Specialists, Association for Research in Vision and Ophthalmology, Michigan Society of Eye Physicians & Surgeons, Michigan State Medical Society

Disclosure: Nothing to disclose.

Asheesh Tewari, MD Michigan Retina Center, PC

Asheesh Tewari, MD is a member of the following medical societies: American Academy of Ophthalmology, American Society of Retina Specialists, Michigan Society of Eye Physicians & Surgeons, Michigan State Medical Society

Disclosure: Serve(d) as a director, officer, partner, employee, advisor, consultant or trustee for: Dutch Ophthalmic.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Martin B Wax, MD Professor, Department of Ophthalmology, University of Texas Southwestern Medical School; Vice President, Research and Development, Head, Ophthalmology Discovery Research and Preclinical Sciences, Alcon Laboratories, Inc

Martin B Wax, MD is a member of the following medical societies: American Academy of Ophthalmology, American Glaucoma Society, Society for Neuroscience

Disclosure: Nothing to disclose.

Hampton Roy, Sr, MD † Associate Clinical Professor, Department of Ophthalmology, University of Arkansas for Medical Sciences

Hampton Roy, Sr, MD is a member of the following medical societies: American Academy of Ophthalmology, American College of Surgeons, Pan-American Association of Ophthalmology

Disclosure: Nothing to disclose.

Bradford Shingleton, MD Assistant Clinical Professor of Ophthalmology, Harvard Medical School; Consulting Staff, Department of Ophthalmology, Massachusetts Eye and Ear Infirmary

Bradford Shingleton, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Ophthalmology

Disclosure: Nothing to disclose.

Iqbal Ike K Ahmed, MD, FRCSC Clinical Assistant Professor, Department of Ophthalmology, University of Utah

Iqbal Ike K Ahmed, MD, FRCSC is a member of the following medical societies: American Academy of Ophthalmology, American Society of Cataract and Refractive Surgery, Canadian Ophthalmological Society, Ontario Medical Association

Disclosure: Nothing to disclose.

Baseer U Khan, MD

Baseer U Khan, MD is a member of the following medical societies: Canadian Ophthalmological Society

Disclosure: Nothing to disclose.

Khalid Hasanee, MD Glaucoma and Anterior Segment Fellow, Department of Ophthalmology, University of Toronto

Khalid Hasanee, MD is a member of the following medical societies: Canadian Medical Association, Canadian Ophthalmological Society, Ontario Medical Association

Disclosure: Nothing to disclose.

Jacqueline Freudenthal, MD Co-Investigator, Ophthalmic Consultants Centre, Toronto

Jacqueline Freudenthal, MD is a member of the following medical societies: American Academy of Ophthalmology, Association for Research in Vision and Ophthalmology, Canadian Ophthalmological Society

Disclosure: Nothing to disclose.

Yasser A Khan, MD Consulting Staff, Credit Valley Eye Care

Yasser A Khan, MD is a member of the following medical societies: Canadian Medical Association, Canadian Ophthalmological Society, and Royal College of Physicians and Surgeons of Canada

Disclosure: Nothing to disclose.

• Print this section
• Print the entire contents of
• Print the entire contents of article